PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34178799-12	2021	Conclusion: The application of sodium valproate combined with levetiracetam in the treatment of pediatric epilepsy is helpful to improve the overall therapeutic effect, significantly improve the cognitive function of children, and improve the levels of NGF, GABA and NSE.	Valproic Acid	31-47	enolase 2	Homo sapiens	267-270	
32782515-0	2020	Sodium valproate combined with levetiracetam in pediatric epilepsy and its influence on NSE, IL-6, hs-CRP and electroencephalogram improvement.	Valproic Acid	0-16	enolase 2	Homo sapiens	88-91	
32782515-1	2020	Efficacy of sodium valproate combined with levetiracetam (LEV) in pediatric epilepsy and its influence on neuron-specific enolase (NSE), interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hs-CRP) as well as electroencephalogram (EEG) improvement were studied.	Valproic Acid	12-28	enolase 2	Homo sapiens	106-129	
32782515-1	2020	Efficacy of sodium valproate combined with levetiracetam (LEV) in pediatric epilepsy and its influence on neuron-specific enolase (NSE), interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hs-CRP) as well as electroencephalogram (EEG) improvement were studied.	Valproic Acid	12-28	enolase 2	Homo sapiens	131-134	
32782515-8	2020	In the treatment of pediatric epilepsy, sodium valproate combined with LEV produces better efficacy, fewer adverse reactions, significantly improves patients" QOL and notably lowers the content of NSE, IL-6 and hs-CRP with notable EEG improvement, so it is a safe and reliable treatment that is worth popularization.	Valproic Acid	40-56	enolase 2	Homo sapiens	197-200	
34630611-8	2021	After treatment, the levels of NSE, MBP, TNF-alpha, and IL-6 in the two groups decreased, and the levels of BDNF increased, and the LEV group changed significantly compared with the VPA group (P < 0.05).	Valproic Acid	182-185	enolase 2	Homo sapiens	31-34